An ozekibart reminder about liver toxicity
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
One of Adcetris’s twin sons strikes out
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Amgen's $1.9bn looks buried
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Caribou finds a match
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Henlius goes on the anti-Pfizer offensive
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
GSK’s trio of cancer discontinuations
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
